Current disruptions are increasing demand for business intelligence and causing sponsors and CROs to rethink their dependence on traditional business processes.
COVID-19 has disrupted clinical trials in many ways. Patients aren’t getting to sites. CRAs aren’t traveling. Physicians and medical staff aren’t as available to support trials. The FDA has issued emergency guidance for the pandemic, urging sponsors and CROs to find alternate ways of ensuring patient safety or give up their studies altogether.